Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel on Thursday initiated coverage on Immunic Inc. (NASDAQ: IMUX), a late-stage biotechnology company developing oral therapies for neurologic and gastrointestinal diseases.